EPS (Diluted) for Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's current diluted EPS (TTM) is $8.83. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingEPS (Diluted)Switch metric
TTM (last 4 quarters)
$8.83
YoY change
-21.1%
5Y CAGR
-18.7%
Peak year (2019)
$31.42
Latest annual
$8.83
EPS (Diluted) history chart for Biogen (BIIB) from 1985 to 2025
EPS (Diluted) history table for Biogen (BIIB) from 1985 to 2025
| Fiscal year | Period ended | Reported | EPS (Diluted) | YoY |
|---|---|---|---|---|
| 2025 | $8.83 | -21.1% | ||
| 2024 | $11.19 | +40.4% | ||
| 2023 | $7.97 | -61.8% | ||
| 2022 | $20.87 | +100.7% | ||
| 2021 | $10.40 | -58.1% | ||
| 2020 | $24.80 | -21.1% | ||
| 2019 | $31.42 | +45.6% | ||
| 2018 | $21.58 | +81.0% | ||
| 2017 | $11.92 | -29.6% | ||
| 2016 | $16.93 | +10.4% | ||
| 2015 | $15.34 | +24.0% | ||
| 2014 | $12.37 | +58.4% | ||
| 2013 | $7.81 | +35.6% | ||
| 2012 | $5.76 | +14.3% | ||
| 2011 | $5.04 | +27.9% | ||
| 2010 | $3.94 | +17.6% | ||
| 2009 | $3.35 | +26.4% | ||
| 2008 | $2.65 | +33.2% | ||
| 2007 | $1.99 | +215.9% | ||
| 2006 | $0.63 | +34.0% | ||
| 2005 | $0.47 | +571.4% | ||
| 2004 | $0.07 | -102.7% | ||
| 2003 | $-2.62 | -624.0% | ||
| 2002 | $0.50 | -26.5% | ||
| 2001 | $0.68 | -5.6% | ||
| 2000 | $0.72 | +53.2% | ||
| 1999 | $0.47 | +213.3% | ||
| 1998 | $0.15 | +55.9% | ||
| 1997 | $0.10 | +119.1% | ||
| 1996 | $0.04 | +448.8% | ||
| 1995 | $0.01 | -233.3% | ||
| 1994 | $-0.01 | -115.0% | ||
| 1993 | $0.04 | -11.1% | ||
| 1992 | $0.04 | +571.6% | ||
| 1991 | $0.01 | +103.0% | ||
| 1990 | $0.00 | -59.8% | ||
| 1989 | $0.01 | -264.0% | ||
| 1988 | $-0.01 | -88.5% | ||
| 1987 | $-0.04 | -27.8% | ||
| 1986 | $-0.06 | +38.6% | ||
| 1985 | $-0.04 | — |
EPS (Diluted) values are taken from Biogen's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual diluted EPS for Biogen (BIIB) came in at $8.83 – declined 21.1% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Biogen diluted EPS compounded at -18.7% per year, with a net decline across the window.
Between 2019 and 2025, Biogen diluted EPS plunged 71.9%, falling from $31.42 to $8.83.
2019 marks the peak diluted EPS at $31.42, with the historical low of $-2.62 recorded in 2003.
Within Healthcare, Biogen (BIIB) ranks 7th among 8 peers we track. The peer median for diluted EPS is $13.16.
Biogen EPS (Diluted) by Year
Biogen EPS (Diluted) 2025: $8.83
Biogen diluted EPS in 2025 was $8.83, declined 21.1% below 2024.
Biogen EPS (Diluted) 2024: $11.19
Biogen diluted EPS in 2024 was $11.19, surged 40.4% from 2023.
Biogen EPS (Diluted) 2023: $7.97
Biogen diluted EPS in 2023 was $7.97, plunged 61.8% below 2022.
Biogen EPS (Diluted) 2022: $20.87
Biogen diluted EPS in 2022 was $20.87, surged 100.7% from 2021.
Biogen EPS (Diluted) 2021: $10.40
Biogen diluted EPS in 2021 was $10.40.
See more financial history for Biogen (BIIB).
Sector peers — EPS (Diluted)
Companies in the same sector as Biogen, ranked by their latest diluted EPS.
| Company | EPS (Diluted) | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $23.03 | Healthcare |
| Eli Lilly and Company (LLY) | $22.95 | Healthcare |
| Amgen Inc. (AMGN) | $14.23 | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $13.23 | Healthcare |
| AstraZeneca PLC (AZN) | $13.08 | Healthcare |
| Johnson & Johnson (JNJ) | $11.03 | Healthcare |
| Merck & Co., Inc. (MRK) | $7.28 | Healthcare |
| AbbVie Inc. (ABBV) | $2.37 | Healthcare |
Frequently asked questions
What is Biogen's diluted EPS?
- Latest reported diluted EPS for Biogen (BIIB) is $8.83 (period ending December 31, 2025).
How has Biogen diluted EPS changed year-over-year?
- Biogen (BIIB) diluted EPS changed -21.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen diluted EPS?
- Biogen (BIIB) diluted EPS compound annual growth rate is -18.7% over the most recent 5 years available.
When did Biogen diluted EPS hit its highest annual value?
- Biogen diluted EPS reached its highest annual value of $31.42 in 2019.
What was Biogen diluted EPS in 2024?
- Biogen (BIIB) diluted EPS in 2024 was $11.19.
What was Biogen diluted EPS in 2025?
- Biogen (BIIB) diluted EPS in 2025 was $8.83.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.